- Home
- SLM vs PTGX Comparison
SLM vs PTGX Comparison
Compare SLM & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLM
- PTGX
- Stock Information
- Founded
- SLM 1972
- PTGX 2006
- Country
- SLM United States
- PTGX United States
- Employees
- SLM N/A
- PTGX N/A
- Industry
- SLM Finance: Consumer Services
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- SLM Finance
- PTGX Health Care
- Exchange
- SLM Nasdaq
- PTGX Nasdaq
- Market Cap
- SLM 5.9B
- PTGX 5.0B
- IPO Year
- SLM N/A
- PTGX 2016
- Fundamental
- Price
- SLM $28.28
- PTGX $85.60
- Analyst Decision
- SLM Buy
- PTGX Strong Buy
- Analyst Count
- SLM 12
- PTGX 9
- Target Price
- SLM $33.67
- PTGX $86.44
- AVG Volume (30 Days)
- SLM 3.0M
- PTGX 954.4K
- Earning Date
- SLM 10-23-2025
- PTGX 11-06-2025
- Dividend Yield
- SLM 1.84%
- PTGX N/A
- EPS Growth
- SLM N/A
- PTGX N/A
- EPS
- SLM 2.84
- PTGX 0.72
- Revenue
- SLM $1,460,617,000.00
- PTGX $209,217,000.00
- Revenue This Year
- SLM $6.00
- PTGX N/A
- Revenue Next Year
- SLM $16.24
- PTGX $140.23
- P/E Ratio
- SLM $9.91
- PTGX $117.81
- Revenue Growth
- SLM N/A
- PTGX N/A
- 52 Week Low
- SLM $23.57
- PTGX $33.31
- 52 Week High
- SLM $34.97
- PTGX $93.25
- Technical
- Relative Strength Index (RSI)
- SLM 58.54
- PTGX 70.25
- Support Level
- SLM $25.95
- PTGX $76.70
- Resistance Level
- SLM $27.12
- PTGX $80.43
- Average True Range (ATR)
- SLM 0.94
- PTGX 2.98
- MACD
- SLM 0.14
- PTGX 0.45
- Stochastic Oscillator
- SLM 57.46
- PTGX 91.14
About SLM SLM Corporation
SLM Corp is an education solutions company. It business is to originate and service loans to students and their families to finance the cost of their education. The provide Private Education Loans to mean education loans to students or their families that are not made, insured, or guaranteed by any state or federal government.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.